COMPASS Pathways Plc stocks have been trading up by 5.68 percent following upbeat coverage of its late-stage psychedelic therapies.
Click Here for a Millionaire's POV on Trading CMPS
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
What Traders Need To Know
- Shares of COMPASS Pathways Plc (CMPS) ripped 42%–49% on heavy volume after a U.S. executive order fast-tracked access to treatments for serious mental illness, igniting psychedelic-therapy names.
- The company is backing this move with two positive Phase 3 COMP360 psilocybin trials in treatment-resistant depression and a rolling NDA process already underway with the FDA.
- A White House order adds priority review vouchers, $50M in ARPA-H funding, and faster rescheduling reviews after successful Phase 3 data, which could directly support CMPS’s regulatory path.
- A new U.S. grant program will fund external groups training clinicians on COMP360 delivery post-approval, signaling that COMPASS Pathways Plc is already planning commercialization logistics.
- A collaboration with Osmind’s 1,000+ psychiatry clinics aims to design how real-world practices can deliver COMP360 therapy, with CMPS trading higher on the operational-scale story.
Weekly Update Apr 20 – Apr 24, 2026: On Friday, April 24, 2026 COMPASS Pathways Plc stock [NASDAQ: CMPS] is trending up by 5.68%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
Compass Pathways (CMPS) is a late‑stage, single‑asset‑dominant psychedelic biotech with no revenue and a highly dilutive loss profile, but with a de‑risked Phase 3 program in treatment‑resistant depression and a rolling NDA underway. Q3 2025 showed net income of –$138m and EBITDA of –$137m, implying an unsustainably high burn versus scale. Cash of ~$186m and working capital of ~$45m provide roughly 5–7 quarters of runway, depending on trial and commercial build‑out intensity, making additional equity or partnerships likely.
Technically, CMPS has pulled back from the post‑EO spike but is stabilizing. This week’s prints show recovery from an 8.65 low to a 9.62 close, reclaiming prior breakdown levels with higher closes and intraday higher lows, suggesting buyers are defending the high‑8s. Five‑minute tape shows heavy volume absorption around 9.00–9.20. The dominant near‑term trend is constructive consolidation; 9.00 is key support. A tactical long entry near 9.00 with a stop ~8.60 targets a move back toward 10.50.
More Breaking News
- The Trade Desk Stock Slides As Legal, Leadership, And Target Cuts Pile Up
- Lightwave Logic (LWLG) Stock Breaks Out As Traders Eye Insider Filings
- SIDU Stock Holds Gains As Lonestar Deal Expansion Fuels Hype
- DCX Stock Holds Key Levels As Volatility Picks Up
Recent news flow is among the strongest in the psychedelic space: two positive Phase 3 trials, a rolling NDA, a favorable White House executive order, and commercialization groundwork via training grants and the Osmind collaboration. CMPS now screens as a top‑tier regulatory asset in psychedelics versus healthcare and biotech benchmarks, albeit with binary risk and heavy cash burn. Base case is constructive: accumulate on pullbacks with support at 9.00, major support near 8.50, and a 6–12 month upside target of 13–15.
Quick Financial Overview
The tape around CMPS reflects a momentum reset after the executive order catalyst. Weekly prices show a pullback from the post-spike area, with recent closes slipping from the mid-$9s to around $9.30–$9.70, suggesting digestion after the violent move higher. For short-term traders, that range is now the active battleground between late buyers and early profit-takers.
Intraday, CMPS spent most of the day between $9.30 and $9.65, with repeated pushes toward the high-$9.50s that failed to extend. This tells you supply is showing up near $9.60–$9.70, while dips toward $9.30 drew demand. In simple terms, you have a developing intraday range with clear reference points for breakout or breakdown trades.
Fundamentally, COMPASS Pathways Plc is still a clinical-stage biotech burning cash. The latest quarter shows a net loss of about $137.7M, negative free cash flow near $35.1M, and a very weak return on capital of roughly -67.55. Yet the balance sheet carries about $185.9M in cash against total liabilities of $218.0M, plus book value per share around $4, so CMPS is trading at more than double book. For traders, this is a classic high-risk, high-upside setup tied to trial data and FDA timing, not current earnings.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.